Immuron (IMRN) Stock Highlights

1.91 | -3.05%

2024-10-21 05:56:42

Immuron Ltd is a clinical-stage biopharmaceutical company focused on the development and commercialization of a novel class of immunomodulator polyclonal antibodies to treat liver diseases, infectious diseases and other immune-mediated diseases, such as colitis. The companys product, IMM-124E, is a proprietary immunomodulatory agent targeted at GI immune-mediated diseases including fatty liver diseases. The company functions in two segments namely, Research and Development and Hyperimmune products.

Statistics

Range Today

1.9 2.02

Volume Today 4.3K

Range 1 Year

1.48 5.96

Volume 1 Year 58.04M

Range 3 Year

1.39 5.96

Volume 3 Year 164.92M

Range 10 Year

1.39 28.99

Volume 10 Year 436.27M

Highlights

Market Capitalization 12.07M (micro)

Floating Shares 195.14M

Current Price 1.91

Price To Earnings -2.47

Price To Revenue 86.48

Price To Book 34.11

Earnings Per Share -0.81

Payout Ratio 0%

Performance

Latest -3.05%

1 Month -25.97%

3 Months -30.04%

6 Months -22.04%

1 Year +3.24%

3 Years -47.24%

5 Years -42.5%

10 Years -79.35%

Benchmarks

Market Capitalization

0 / 368

Gross Profits

0 / 278

Total Revenue

0 / 300

Total Rank

0 / 368

Free Cashflow

0 / 352

Performance 5 years

0 / 368

Obligatory risk notice

We would like to point out that the contents of this website are for general information purposes only and do not constitute recommendations for the purchase or sale of specific financial instruments, and therefore do not constitute investment advice. In particular, marketstorylabs.com and its creators cannot assess the extent to which information / recommendations made on the pages correspond to your investment objectives, your risk tolerance and your ability to bear losses. Therefore, if you make any investment decisions based on information on the site, you do so solely on your own responsibility and at your own risk. This in turn means that neither marketstorylabs.com nor its creators are liable for any losses incurred as a result of investment decisions based on the information on the marketstorylabs.com website or other media used.